An article in “El Punt Avui” newspaper mentions the most recent advances made by the Peptides and Proteins Laboratory at IRB Barcelona, headed by Ernest Giralt, also full professor at the UB. This lab has identified several substances capable of transporting drugs across the barrier that protects the brain from infections. The article includes statements made by Giralt and explains the projects underway in his lab to find treatments for various neurological diseases and tumours.
Read the article in El Punt Avui (in Catalan)
“El País” has included an article about Spark, the project started by the public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off. IRB Barcelona, CRG, the University of the Basque Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project. The article includes statements by Teresa Tarragó, researcher at IRB Barcelona and co-founder of Iproteos, and Miquel Bernardo, director of the Schizophrenia Unit at the Hospital Clínic and main researcher of the Mental Health network CIBERSAM.
Read the article in El País (in Spanish)
TV3 News has broadcasted a report on a shuttle molecule capable of crossing the barrier that protects the brain from infections and of transporting therapeutic molecules into this organ —a development patented by members of the Peptides and Proteins Laboratory at IRB Barcelona, headed by Ernest Giralt, also full professor at the UB. In the report, Giralt explains how this shuttle works. His lab is already working on the applications of this shuttle in three projects to treat various diseases that affect the brain.
Watch the video on...
Radio 5 (RNE) has reported on the “Spark” project, launched by the public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off. IRB Barcelona, CRG, the University of the Basque Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project. The program includes statements by Javier Meana, researcher at the University of the Basque Country, and Teresa Tarragó, researcher at IRB Barcelona and co-founder of Iproteos.
Listen to the news on Radio 5 (04:30 minutes, in Spanish)
Radio Euskadi interviews Meritxell Teixidó, associate researcher in the Peptide and Protein Laboratory at IRB Barcelona, about the development of a shuttle peptide capable of crossing the blood-brain barrier and carrying therapeutic molecules in to this organ to treat diseases of the central nervous system. In the interview, Teixidó talks about how the shuttle works and about its potential therapeutic applications.
Listen to the interview on Radio Euskadi (10:36 minutes, in Spanish)
Wide coverage in the media about a breakthrough by Ernest Giralt’s group that was presented yesterday in Angewandte Chemie. Specifically, this group has developed and patented a peptide shuttle able to transport substances to the brain. This shuttle has the capacity to cross the blood-brain barrier, a natural defence structure that prevents substances from passing into the brain, thus protecting it against infection. However, this barrier is also a severe obstacle for therapeutics as 98% of promising drugs for the treatment of central nervous system cannot cross it. “Many companies could recover promising molecules that were once discarded and attach them to our shuttles,” comment the...
Chemists at IRB Barcelona patent and present a shuttle capable of transporting molecules into the brain; this achievement could facilitate the treatment of diseases with no therapy available.
98% of drugs targeting the central nervous system are discarded because they are unable to cross the physical barrier that protects the brain.
The IRB Barcelona scientists, together with clinical teams, are now evaluating the potential of their shuttle for rare and orphan diseases.
Various new bulletins on RAC1 radio have included statements by Ernest Giralt, group leader of the Peptide and Protein Laboratory at IRB Barcelona, following the publication of an article on the compound created by his lab that is capable of transporting drugs in to the brain.
The Council recognizes the impact of his research in peptide chemistry with applications in innovative therapies for cancer
The "Ciutat de Barcelona" prize represents the highest recognition that gives the city to its citizens
SmartQuimic has interviewed Teresa Tarragó and Ernest Giralt, IRB Barcelona researchers and co-founders of the spin-off Iproteos, granted the EXPOQUIMIA ’14 award for the creation of IRP19, a new drug for treating cognitive deficits associated with schizophrenia.
Read the interview in SmartQuimic